allogeneic; autologous; hematopoietic cell transplantation; Philadelphia chromosome (Ph þ ) ALL has served as the model for the cure of neoplasia by chemotherapy for several decades, but even now, fewer than half of adult patients achieve long disease-free survival (DFS). Steady improvements in the cure rate for adults have been achieved through more accurate diagnoses, the use of intensive multiagent chemotherapy, attention to potential sanctuary sites such as the central nervous system (CNS) and the appropriate use of allogeneic hematopoietic cell transplantation (Allo-HCT). Further progress will require large numbers of uniformly evaluated patients to be entered onto randomized clinical trials, testing various components of the total therapy that have heretofore been added empirically. The ability to detect minimal residual disease during remission may identify patients who require alternative treatment and at the same time spare some patients from unnecessarily prolonged or toxic treatments. New drugs will likely be required for a breakthrough in the cure rate.
Treatment regimens for ALL have evolved empirically into complex schemes that use numerous agents in various doses, combinations and schedules. Few of the individual components have been tested rigorously in randomized trials. Thus, it is difficult to analyze critically the absolute contribution of each drug or dose schedule to the ultimate outcome. Numerous nonrandomized trials have attempted to answer these questions, but multiple alterations in study design between sequential trials have made it difficult to assess the exact merit of each modification. In addition, ALL is quite a heterogeneous disease, and outcomes vary by age, immunophenotype and clinical, cytogenetic and molecular features. This review will examine recent clinical trials that have used Allo-HCT within the context of modern risk-adapted treatment of ALL in adults.
Risk assessment
In analyses that included over 350 adults with ALL treated on prospective trials with intensive chemotherapy, the Cancer and Leukemia Group B (CALGB) identified the following clinical and biologic features, which correlated with favorable long-term outcome: younger age (o60 years old), WBC o30 000/ml, the presence of a mediastinal mass, T-cell immunophenotype (with or without myeloid markers) and the absence of the Philadelphia (Ph) chromosome. 1 Patients who had no adverse features had a 91% estimated probability of survival at 3 years (95% confidence interval, 66-98%). Patients with one, two, or three unfavorable features had 3-year survivals of 64, 49, and 21%, respectively. None of the patients with four adverse risk factors survived more than 3 years. Survival was a continuous function of age. The survival at 3 years for patients o30 years old was 66% and for those 30-59 years old was 36%. Very few of these patients underwent Allo-HCT in the first CR (CR1). Similar models have been described by others, but importantly, the risk groups vary and are dependent upon particular therapies. 2 In particular, prognostic factors are different when analyzing outcomes after myeloablative therapy and HCT. Universally, older age (435 or 440 years old) or Ph þ ALL have been considered high-risk features.
Most recently, attention has focused on adolescents and young adults (age: 16-30 years old) with ALL. Teenage patients are treated by either adult or pediatric hematologists, and several retrospective studies have reported that adolescents with ALL have had better outcomes when treated on prospective pediatric protocols than when enrolled on adult ALL protocols. 3 Prospective trials are currently evaluating the outcomes of young adults when treated by adult hematologists using pediatric regimens.
Better results from chemotherapy would impact considerably on the need for Allo-HCT in this favorable group.
HCT has been utilized in the remission consolidation phase of treatment with the hope that myeloablative chemotherapy and/or TBI would more effectively eradicate subclinical disease. 4 This has been shown to be beneficial in most, but not all, studies in patients with high-risk disease receiving Allo-HCT (but not autologous HCT) in CR1. [4] [5] [6] [7] [8] [9] [10] ( Tables 1 and 2 ) The enthusiasm for HCT for all patients in CR1, however, has been tempered by several studies that fail to demonstrate a significant survival advantage of HCT over chemotherapy as consolidation, especially for those with standard risk features. 4, [11] [12] [13] In some cases, for example, T-cell ALL with TLX1 (HOX11) expression, early Allo-HCT may diminish the excellent outcomes obtained with chemotherapy alone. 14 There is clearly more treatment-related mortality as well as later morbidity (especially GVHD, chronic cytopenias, infection, loss of fertility, cataracts and second malignancies) after Allo-HCT than after chemotherapy alone. However, the relapse rate is clearly reduced by allogeneic transplantation. Marks et al. 15 evaluated pooled registry data regarding conditioning regimens used for 502 matched-sibling allografts for children and adults (o56 years old) with ALL in CR1 or CR2 (second CR). All received a TBI-containing combination. Treatment-related mortality did not differ whether Cy or etoposide was included, nor were there significant differences for relapse rate, leukemia-free survival or overall survival (OS) in CR1 by conditioning regimen.
It has not been feasible to randomize patients with an HLA-matched sibling donor to an Allo-HCT compared to chemotherapy. 16, 17 Thus, 'genetic randomization' or assignment to HCT for those who have suitable donors has typically been used to evaluate the benefit of allografts in CR1. An intention-to-treat analysis then evaluates outcomes from a 'donor-no donor' comparison.
Allogeneic HCT in the first complete remission
Between 1986 and 1991, the Leuce´mie Aigue¨Lymphoblas-tique de l'Adulte performed a prospective, multicenter study (LALA-87) in adult ALL patients comparing relateddonor Allo-HCT, autologous HCT and chemotherapy (Table 1) . 5, 6 At CR1, 436 patients and their siblings were HLA-typed and those 15-40 years old with an available donor (n ¼ 116) were assigned to an Allo-HCT using BM stem cells; 98 patients were actually transplanted. Patients o40 years old with no available related donor plus patients Table 1 Outcomes from the French multicenter study LALA-87 5, 6 BMT group Control group P-value 40-50 years old (n ¼ 262) were randomized to receive either an autologous BMT (n ¼ 95 were randomized; 63 patients actually received BMT) or chemotherapy (n ¼ 96). All patients over 50 years of age were treated with chemotherapy (n ¼ 58). Median time from CR to Allo-BMT was 63 days, and median time from CR to autologous BMT was 116 days. At a median follow-up of 38 months, there were no significant differences between the autologous BMT and chemotherapy groups in either 3-year DFS (39 vs 32%; P ¼ 0.8) or 3-year OS (49 vs 42%; P ¼ 0.9). By intention-totreat, the Allo-BMT group had a 3-year DFS of 43% and a 3-year OS of 55%. The chemotherapy group (age 450 years) had a 3-year DFS of 24% and a 3-year OS of 28%.
Sebban et al. 9 later reported the results of a donor-no donor comparison from the LALA-87 trial: 116 patients with an HLA-matched donor (of whom 92 were actually transplanted in CR1) were compared with a no-donor control group, consisting of 141 patients who had received either an autologous BMT or chemotherapy only. Median ages were 26 and 24 years old, respectively. No significant differences in DFS (median, 24 months vs 22 months; P ¼ 0.1) or OS (median, 51 vs 30 months; P ¼ 0.08) were observed.
Within a subset of 96 patients with high-risk ALL, a significant benefit for Allo-BMT (n ¼ 41) was observed compared with chemotherapy (n ¼ 55) with respect to DFS (median, 21 vs 9 months; P ¼ 0.01) and OS (median, 30 vs 15 months; P ¼ 0.03). However, there was no difference in DFS or OS between the Allo-BMT and chemotherapy groups among standard risk ALL patients. High-risk ALL patients had at least one of the following: (1) Ph þ chromosome, (2) null leukemia or undifferentiated leukemia and (3) precursor B-cell ALL with at least one adverse prognostic factor (age 435 years, WBC 430 000/ml or 44 weeks to achieve CR1).
A subsequent trial by the same group (LALA-94) between 1994 and 2002 compared related Allo-HCT, autologous HCT and chemotherapy in 922 adults (15-55 years old) with ALL (Table 2) ; 84% achieved CR1. 7 Standard risk patients (n ¼ 307) received only chemotherapy; this group included all T-ALL patients achieving CR after one course of chemotherapy, B-lineage ALL patients with no CNS involvement, plus those with the absence of Ph þ , t(4;11), t(1;19) or other 11q23 rearrangements, plus WBC count o30 000/ml, CD10 þ /CD19 þ immunophenotype, CD20 þ /CD19 þ immunophenotype and the absence of myeloid markers and achievement of CR after one course of chemotherapy. Their 5-year OS was 44%. Patients with high-risk clinical features, but without Ph þ ALL or CNS þ ALL, who achieved a CR (n ¼ 211) and did not have a sibling donor (n ¼ 129) were randomized to receive autologous HCT followed by 2 years of maintenance with MTX and mercaptopurine (n ¼ 70) or to chemotherapy alone (n ¼ 59). After a median follow-up of 5.2 years, the 3-year DFS for autologous HCT vs chemotherapy was 39 vs 24% (P ¼ NS). The 82 highrisk patients with an HLA-matched sibling donor were assigned to a related Allo-HCT. Conditioning regimens for both autologous and Allo-HCT were Cy þ TBI (1000 cGy in a single fraction, or 1200 cGy in six fractions).
Patients with Ph þ ALL who achieved CR1 were assigned to receive a related Allo-HCT if a suitable donor was available or an autologous SCT if not; their results are described later. 8 A fourth group of 48 patients with CNS þ ALL who achieved CR1 were biologically randomized to receive a related Allo-HCT if a suitable donor were available (n ¼
, were in CR1 and were 15-45 years of age. Adjustments were made for time to transplant bias and differences in disease characteristics. Prognostic factors for treatment failure were similar for both groups: immunophenotype, WBC count at diagnosis and time to achieve CR1. Five-year DFS was not significantly different between the two groups: 38% (95% CI, 33-43%) for the chemotherapy group and 44% (95% CI, 37-52%) for the Allo-BMT group. Zhang et al.
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reported long-term follow-up of the same patients. With 4 additional years of follow-up (median, 7.5 years), the 9-year DFS was 32% in the chemotherapy group and 34% in the related Allo-BMT group (P40.2). The incidence of relapse was 66% in the chemotherapy group and 30% for the HCT group (Po0.0001).
Ribera et al.
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recently reported results from the PETHEMA ALL-93 trial, which enrolled 222 adults (15-50 years old) with high-risk precursor-B ALL. High risk was defined as age 30-50 years old, WBC count 425 000/ml or adverse cytogenetics (Ph þ , t(4;11), other 11q23 rearrangements or t (1;19) ). Post-remission therapy used a myeloablative allograft (N ¼ 84) or patients were randomized to an autologous HCT (N ¼ 50) or chemotherapy (N ¼ 48). A donor vs no-donor comparison revealed no significant differences in OS at 5 years (35 vs 44%; P ¼ 0.35). These results did not differ when the Ph þ ALL patients (37% of the total) were excluded.
Gupta et al. 18 reported a single center experience between 1992 and 2001 wherein all adults (16-55 years old) with ALL in CR1 were offered a matched related Allo-BMT if any donor were available (n ¼ 48); 35 were HLA-identical siblings, four were one-antigen mismatch and nine were unrelated donors. Otherwise, only chemotherapy was given to 39 patients. After a median follow-up of 52 months, an intent-to-treat analysis showed no significant differences in 3-year OS or event-free survival (EFS) between the donor and no-donor groups. There were still no significant differences in EFS or OS after excluding the 17 patients with Ph þ ALL.
Ringden et al. 19 compared the results of 826 adults (416 years) with ALL treated with HLA-identical related Allo-BMT to 345 adults treated with HLA-identical related allogeneic PBSC transplantation (PBSCT) reported to the European Bone Marrow Transplant (EBMT) Registry between 1994 and 2000. Sixty-two percent of the BMT recipients were in CR1 at the time of transplant, 18% were in CR2 and 20% had more advanced disease. The corresponding numbers for the PBSCT recipients were 55% CR1, 20% CR2 and 25% more advanced. Nine percent of the BMT and 17% of the PBSCT donor grafts were T-cell depleted. TBI-based conditioning regimens were used in 82% of the BMT and 69% of the PBSCT patients. Engraftment was significantly faster in the PBSCT group (mean time to absolute neutrophil count 4500/ml was 14 vs 19 days; Po0.0001). By multivariate analysis, there was no significant difference between the BMT and PBSCT groups with regard to acute or chronic GVHD, treatment-related mortality, DFS or OS. The only significant multivariate risk factors for improved DFS and OS were disease status at transplant (CR14CR24advanced disease) and MTX-containing immunosuppression for GVHD prophylaxis.
Preliminary data from the largest adult ALL trial to date (MRC-ECOG UKALLXII/E2993) were recently reported in an abstract by Rowe et al. 10, 20 Patients up to age 60 years (65 since 2004) received two phases of induction. In CR1, patients o50 years (55 since 2004) were assigned to Allo-HCT if they had a compatible sibling donor. The others were randomized to consolidation/maintenance therapy for 2.5 years or to a single autologous transplant. Before the assigned or randomized therapy, all patients received intensification with three courses of high-dose MTX. Over 1980 patients were entered, 91% achieved a CR and 919 patients without Ph þ ALL agreed to post-remission therapy according to protocol (Table 3) . Estimated OS at 5 years was 53% for those assigned to Allo-HCT and 45% for those receiving autologous HCT or chemotherapy (P ¼ 0.02). High-risk clinical features, defined as one of the following: age 435 or a high WBC count (430 000/ml for B-lineage or 4100 000/ml for T-ALL) were present in 400 patients. In a donor vs no-donor analysis, patients with a sibling donor (n ¼ 384) had improved OS and EFS and a significantly lower relapse. However, this advantage was confined to standard-risk patients. The lack of demonstrable survival benefit in high-risk patients was due to high treatment-related mortality associated with age 435 years; the 2-year nonrelapse mortality for these patients with a donor was 39% (high risk) and 20% (standard risk) compared with 12% (high risk) and 7% (standard risk) for those without a donor. In an intention-to-treat analysis of chemotherapy vs autologous HCT, patients receiving chemotherapy only had significantly better EFS. The difference between these two groups was not due to a higher mortality but rather a higher relapse rate after autologous HCT.
Yanada et al. 21 conducted a meta-analysis of published data from seven studies that included 1274 adults with ALL. Patients with donors had a significantly better survival that those in the no-donor groups (hazard ratio, 1.29; 95% confidence interval, 1.02-1.63; P ¼ 0.037). When only high-risk patients were analyzed, the survival advantage was greater (HR, 1.42; 95% CI, 1.06-1.90; P ¼ 0.019). Compliance with the Allo-HCT was positively correlated with survival (Po0.01), suggesting that the higher the proportion of patients who actually received the Allo-HCT, the better the survival for the entire donor group. No beneficial effects were observed from autologous HCT.
Allogeneic HCT for Ph þ ALL
Until the advent of imatinib and newer BCR/ABL tyrosine kinase inhibitors, Allo-HCT was strongly recommended for all adults with Ph þ ALL in CR1 if a suitable donor could be found. However, even an early Allo-HCT was often unsuccessful. Barrett et al. 22 analyzed the outcomes of 67 patients (81% were 416 years old) with Ph þ ALL treated with an HLA-matched sibling BMT and reported to the IBMTR between 1978 and 1990. The Ph þ chromosome was the only karyotypic abnormality in 45 (67%) patients while 22 (33%) patients had additional cytogenetic abnormalities. Conditioning and GVHD prophylaxis regimens varied by reporting center, but 72% of patients received a TBI-containing conditioning regimen. At a median follow-up of 36 months, 33 patients transplanted in CR1 had a 2 year leukemia-free survival of 38% compared with 41% for 22 patients with relapsed ALL and 25% for 12 patients with primary induction failure.
Thirty-three CR1 patients with Ph þ ALL were compared with 33 matched controls selected from 106 PhÀ ALL patients reported to the IBMTR during the same time period and also transplanted in CR1. 22 Controls were matched on age and WBC count at diagnosis and time Table 3 Five-year estimates for OS, EFS and relapse for 919 patients o50 years old with PhÀ ALL in CR1 who received postremission therapy on MRC-ECOG study UKALLXII/E2993 10 
5-year estimates
Patients (no.) OS (%) P EFS (%) P Relapse (%) P from diagnosis to HCT. The Ph þ ALL patients tended to have earlier relapses (34 vs 23% at 2 years) and lower 2-year leukemia-free survival (38 vs 49%) compared to the PhÀ ALL-matched controls; however, these differences were not statistically significant. Snyder et al. 23 reported the results of 23 Ph þ ALL patients (one patient o18 years old) treated with an HLAmatched sibling Allo-BMT in CR1 between 1984 and 1997 at the City of Hope National Medical Center. Patients received etoposide þ TBI (1320 cGy in 11 fractions) or similar TBI regimen for conditioning. At a median followup of 40 months, the 3-year DFS was 65%.
Between 1994 and 2000, Dombret et al. 8 randomized 154 newly diagnosed adults (415 years old) with Ph þ or BCR/ABL þ ALL to receive one of two induction regimens, followed by a single course of intermediate dose cytarabine and mitoxantrone (HAM) in the LALA-94 trial A total of 103 patients in CR after HAM were assigned based on donor availability to either a matched related BMT (n ¼ 46), matched unrelated BMT (n ¼ 14) or autologous HCT (n ¼ 43) at 3 months after consolidation. The conditioning regimen for autologous and related Allo-BMT was Cy þ etoposide þ TBI (1000 cGy in one fraction or 1200 cGy in six fractions) but varied by center for unrelated donor BMT. GVHD prophylaxis also varied by center. HCT was actually performed in 44 (96%) of the matched related, 12 (86%) of the matched unrelated and 24 (56%) of the autologous BMT patients, but the results were reported by intention-to-treat. There was no difference in OS in the matched related vs unrelated BMT groups; therefore, the data were analyzed by donor (n ¼ 60) vs no-donor (n ¼ 43) groups.
The 3-year OS of the no-donor group was significantly lower than the donor group (12 vs 37%; P ¼ 0.02), even after adjustment for age, WBC count and number of chemotherapy courses to achieve CR1. The 3-year incidence of relapse was significantly higher in the no-donor group (90 vs 50%; Po0.001). The 2-year probability of death in CR was equivalent in the donor and no-donor groups (24 vs 24%).
Imatinib, given sequentially or concomitantly with chemotherapy, now plays an important role in the frontline treatment of Ph þ ALL. Once in morphologic and cytogenetic remission, most patients are recommended to undergo allogeneic SCT. More recently, better results have been obtained in the initial treatment of Ph þ ALL when imatinib has been added to chemotherapy. 24 Most patients achieve CR, and many have molecular remissions, and thus are able to proceed rapidly to an HCT. Having observed that relapses were less common among patients who were in morphologic and cytogenetic remission at the time of transplant as well as in those who developed chronic GVHD, Stirewalt et al. 25 at the Fred Hutchinson Cancer Research Center suggested that patients in molecular remission receive less intensive (nonmyeloablative) Allo-HCT.
In a large Japanese study, 80 patients with BCR/ABL þ ALL were treated with imatinib plus combination chemotherapy; 77 (96%) achieved CR at a median time of 28 days. 26 The molecular response rate was 71% and the 1-year OS was 76%. Interestingly, OS at 1 year was 73% for those who underwent Allo-HCT in CR1 (n ¼ 39) or later and 85% for those who did not (P ¼ NS). Although follow-up is still quite short, the outcomes for imatinibtreated patients were considerably better than historical controls, regardless of whether an Allo-HCT or chemotherapy only was used.
Many patients lack an HLA-matched donor and no data have yet shown a benefit from autologous HCT for Ph þ ALL. However, CALGB investigators hypothesized that sequential chemotherapy and imatinib would result in greater leukemia cell cytoreduction than previously achieved with chemotherapy alone, thereby allowing the collection of large number of normal hematopoietic stem cells from the blood uncontaminated by residual Ph þ lymphoblasts. 27 Thus, patients without matched sibling donors might undergo autologous HCT with a lower likelihood of relapse. Patients 15-59 years old with Ph þ ALL who had a CR or PR after one cycle of a four or five drug-induction regimen are eligible for CALGB study 10001. Imatinib (800 mg/day) is given for 4 weeks. CNS prophylaxis is given with high-dose systemic and intrathecal MTX, followed by another 4 weeks of imatinib. Patients without donors receive high-dose cytarabine and etoposide with filgrastim for stem cell mobilization and leukapheresis, followed by autologous HCT after 1320 cGy fractionated TBI, etoposide (60 mg/kg) and Cy (100 mg/kg). Imatinib is held during the transplant period but resumed for maintenance therapy until patients remain RT-PCR negative for 12 months. To date, 35 patients have enrolled; the median age is 47 years (range, ; four were negative for BCR/ABL. Median time to autologous engraftment was 29 days (range, [28] [29] [30] [31] [32] [33] [34] [35] . Two patients have relapsed at 334 and 475 days, and six are in continuous major molecular remission (43 log reduction from pretreatment levels) at a median of 487 days (range, 197-923) . Longer follow-up is required, but sequential chemotherapy and imatinib yields RT-PCR-negative CD34 þ leukapheresis products, allowing autologous SCT for patients without donors. Engraftment is not compromised and post-HCT imatinib is tolerable.
Future progress
Although there as been some success using antibodies or targeted agents such as imatinib for purging, autologous HCT has an unproven benefit in adult ALL. 4, [27] [28] [29] [30] Using DNA sequence typing for HLA alleles, results with matched unrelated donors appear equivalent to those with matched sibling donors. 20, [31] [32] [33] Monitoring for minimal residual disease may identify a subset of ALL patients in CR1 who would most likely benefit from an early Allo-HCT. 34, 35 Nonmyeloablative Allo-HCT for ALL remains under investigation. 36, 37 Conclusions ALL remains a difficult disease to treat, due in part to its biological and clinical heterogeneity. Modern treatment strategies use risk-adapted approaches to increase the cure rate while minimizing toxicities. Available data indicate no consensus as to whether there is an advantage to Allo-HCT over chemotherapy for consolidation of adults with ALL with standard risk features while in CR1. However, Allo-HCT is recommended in CR1 for patients with high-risk ALL, for those in a CR2, and for certain other subsets of patients with this disease. The development of better transplant methods as well as new targeted agents, such as imatinib, may radically change the outcomes for selected patients.
